- Moderna Inc (NASDAQ:MRNA) and Gavi, the Vaccine Alliance, agreed to cancel the remaining pending orders under the current COVID-19 vaccine supply agreement for 2022 based on the original coronavirus strain.
- Instead, Moderna will supply up to 100 million doses of its new, variant-adapted vaccines at its lowest price from 2023.
- Moderna’s agreement with Gavi has led to the supply of nearly 70 million doses of COVID-19 vaccines to the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries, in addition to the company facilitating the donation of more than 100 million doses to these countries.
- Related: US Health Official Says Updated COVID-19 Boosters Should Offer Protection Amid Tracking Emerging Variants.
- GAVI chief executive Seth Berkley said the new agreement was a “critical step for equitable access” to allow lower-income countries to use the modified vaccines as they see fit.
- Many wealthier countries have started using the vaccine in booster campaigns.
- Price Action: MRNA shares are up 4.44% at $139.95 on the last check Monday.
Goldman Sachs Initiates Coverage On Myriad Genetics with Sell Rating, Announces Price Target of $25
Goldman Sachs analyst Matthew Sykes initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Sell rating and announces Price Target of $25.
